CervoMed
CRVO | NASDAQ
$1.67
-$0.02 (-1.18%)
At close: Nov 16, 2026, 4:00 PM ET
$1.65
-$0.02 (-1.16%)
After-hours:
Nov 16, 2026, 7:58 PM ET
CervoMed Company Profile
Company profile explainedCompany Profile
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| John J. Alam | Co-Founder, Chief Executive Officer, President & Director |
| William Robert Elder | Chief Financial Officer, General Counsel & Corporate Secretary |
| Claudia Ordonez | Senior Vice President of Medical Science |
| Kelly Blackburn | Executive Vice President of Clinical Development |
| Marinus Verwijs | Executive Vice President of Technical Operations |
| Mark A. De Rosch | Executive Vice President of Regulatory, Government Affairs & Program Management |
| Matthew Winton | Chief Commercial & Business Officer |
| Sylvie L. Gregoire | Co-Founder & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 23, 2026 | 4 | Filing |
| Oct 23, 2026 | 4 | Filing |
| Oct 23, 2026 | 4 | Filing |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 13, 2026 | 8-K | Current Report |
| Oct 09, 2026 | 8-K | Current Report |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
CervoMed
| Country | United States |
| IPO Date | May 23, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | John J. Alam |
Contact Details
20 Park Plaza Boston,
Massachusetts 02116 United States
Stock Details
| Ticker Symbol | CRVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001053691 |
| CUSIP Number | 15713L109 |
| ISIN Number | US15713L1098 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove CRVO